Current / Ongoing Studies                                                                                                        updated July 2020

No Study Name/Phase Type Sponsor Population (Gender/Age) Enrolled / Target Period
1 HPV vaccine /Phase III HPV vaccine MSD ♀ 9-26 yrs 20 2010 – 2020
2 Menacwy/Phase III Meningococcal vaccine Pfizer ♂/♀ 12-14 M 86 2014 – 2020
3 HDT TB/Phase IIb TB Treatment Aurum Institute ♂/♀ 18-65 yrs 39 2016 – 2020
4 HVTN 702/Phase IIb HIV Vaccine HVTN ♂/♀18-35 yrs 483 2016 – 2021
5 HVTN 705/Phase IIb HIV Vaccine Janssen/HVTN ♀18-35 yrs 144 2018 – 2021
6 NC008/Phase IIc TB Treatment TB Alliance ♂/♀≥18 33 2018 – 2020
7 PrEPARE Study/PrEP Rollout PrEP RTI ♀16-24 yrs  n/a 2019 – 2021
8 MV40618/Phase IIIb Flu treatment (Adults) Roche ♂/♀

Index – 12-64 yrs

Household – ≥2 yrs

0 2019 – 2020
9 EPI RSV RSV study GSK ♀ 18-45 100 2019 – 2020
10 NN9924-4309 (Pioneer 12) Diabetes (China) Novo Nordisk ♂+♀ ≥18 2 2020 – 2022
11 R01 AI147681 KHARITUWE TB STUDY TB Tracing John Hopkins University ♂/♀ 0-99 yrs Target: 1440 2020 – 2025
12 SCHIELD PART 2 DCE’s Behavioural RTI ♀18 – 30 Target: 24 IDI’s,

400 surveys

2020 – 2021
13 ChAdOx1 nCoV-19 Covid Vaccine Bill & Melinda Gates and SAMRC ♂+♀

18-65

Target: 400 2020 – 2021